OCWP
VKTX icon

Owl Creek Wealth Partners’s Viking Therapeutics VKTX Stock Holding History

Owl Creek Wealth Partners’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.17K Hold
30
– – ﹤0.01% 1194
2026
Q1 		$977 Buy
+30
New +$964 ﹤0.01% 1163

Other funds holding VKTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Owl Creek Wealth Partners's VKTX Position: Q2 2026 in Review

Owl Creek Wealth Partners held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 30 shares worth $1.17K. The position accounts for ﹤0.01% of the portfolio, ranked #1194.

Owl Creek Wealth Partners first reported a position in VKTX in Q1 2026 and has held it in 2 quarters since. 402 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Owl Creek Wealth Partners held 30 shares of Viking Therapeutics worth $1.17K as of Q2 2026.
  • Owl Creek Wealth Partners left its Viking Therapeutics share count unchanged in Q2 2026.
  • Viking Therapeutics made up ﹤0.01% of Owl Creek Wealth Partners's portfolio in Q2 2026, its #1194 holding.
  • Owl Creek Wealth Partners first reported a position in Viking Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 402 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Owl Creek Wealth Partners's 13F filing for Q2 2026, filed 20 Jul 2026.